La cadena de opciones muestra datos clave de las opciones de acciones de Syros Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Syros Pharmaceuticals..

Syros Pharmaceuticals (NASDAQ:SYRS) Bolsa, Cadena de Opciones

Syros Pharmaceuticals

Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Syros Pharmaceuticals, Inc. - Common Stock

Syros Pharmaceuticals Inc

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the information technology sector.
<h3 class="wp-block-heading">Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>)</h3>
<ul>
<li>Dividend Yield: 4.10%</li>
<li>Goldman Sachs analyst Toshiya Hari maintained a Neutral rating and cut the price target from $92 to $70 on Feb. 6, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Stifel analyst Ruben Roy downgraded the stock from Buy to Hold and lowered the price target from $105 to $62 on Feb. 6, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Feb. 5, Skyworks issued second-quarter adjusted EPS guidance below estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest SWKS <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="911" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80.png" alt="" class="wp-image-819697" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80.png 911w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195035/image-80-768x704.png 768w" sizes="(max-width: 911px) 100vw, 911px" /></a></figure>
<h3 class="wp-block-heading">HP Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPQ#NYSE">HPQ</a>)</h3>
<ul>
<li>Dividend Yield: 4.05%</li>
<li>Loop Capital analyst Annada Baruah maintained a Hold rating and cut the price target from $35 to $30 on March 4, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from $35 to $36 on Feb. 28, 2025. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On Feb. 27, HP issued second-quarter adjusted EPS guidance below estimates..</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">HPQ news</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/df77bbb1-43a4-4442-b721-878eebbeb2c1" alt="" style="width:587px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Opera Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRA#NASDAQ">OPRA</a>)</h3>
<ul>
<li>Dividend Yield: 4.58%</li>
<li>TD Cowen analyst Lance Vitanza maintained a Buy rating and raised the price target from $25 to $28 on Oct. 30, 2024. This analyst has an accuracy rate of 76%.</li>
<li>B. Riley Securities analyst Lee Krowl reiterated a Buy rating and increased the price target from $24 to $25 on Oct. 30, 2024. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: On Feb. 27, Opera reported better-than-expected fourth-quarter revenue results and issued first-quarter revenue guidance above estimates.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">OPRA news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="906" height="835" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82.png" alt="" class="wp-image-819699" style="width:580px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82.png 906w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11195149/image-82-768x708.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

OPRA

SWKS

Wall Street's Most Accurate Analysts Weigh In On 3 Tech Stocks With Over 4% Dividend Yields

Morgan Stanley analyst Erik Woodring maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Overweight and lowers the price target from $275 to $252.

AAPL

Morgan Stanley Maintains Overweight on Apple, Lowers Price Target to $252

The most oversold stocks in the financial sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the<a href="https://www.benzinga.com/topic/rsi"> RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Payoneer Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYO#NASDAQ">PAYO</a>)</h3>
<ul>
<li>On Feb. 27, Payoneer Global reported worse-than-expected fourth-quarter EPS results. The company's stock fell around 29% over the past month and has a <a href="https://www.benzinga.com/quote/PAYO">52-week low of $4.22</a>.</li>
<li>RSI Value: 28.9</li>
<li>PAYO Price Action: Shares of Payoneer Global gained 0.3% to close at $7.06 on Tuesday.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">PAYO news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77.png" alt="" class="wp-image-819686" style="width:645px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11192933/image-77-768x703.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On March 5, the company disclosed definitive agreements to sell the Japanese supermarket chain Seiyu to Trial Holdings, Inc. for 380 billion yen ($2.5 billion). The company's stock fell around 21% over the past month and <a href="https://www.benzinga.com/quote/KKR">has a 52-week low </a>of $91.92.</li>
<li>RSI Value: 27.8</li>
<li>KKR Price Action: Shares of KKR rose 3.6% to close at $112.11 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">KKR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="922" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78.png" alt="" class="wp-image-819687" style="width:586px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193020/image-78-768x698.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Piper Sandler Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PIPR#NYSE">PIPR</a>)</h3>
<ul>
<li>On March 11, Piper Sandler expanded its research distribution with new office opening in Zurich. The company's stock fell around 18% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/PIPR">low of $183.58.</a></li>
<li>RSI Value: 29.6</li>
<li>PIPR Price Action: Shares of Piper Sandler gained 3.1% to close at $250.49 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">PIPR shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="887" height="833" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79.png" alt="" class="wp-image-819688" style="width:627px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79.png 887w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79-300x282.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/11193110/image-79-768x721.png 768w" sizes="(max-width: 887px) 100vw, 887px" /></a></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

Long Ideas

PAYO

PIPR

Top 3 Financial Stocks That Could Blast Off This Month

<a href="https://www.bakerhughes.com/company/news/us-department-defense-grants-baker-hughes-awardable-status-development-geothermal">https://www.bakerhughes.com/company/news/us-department-defense-grants-baker-hughes-awardable-status-development-geothermal</a>
&nbsp;
<ul>
<li>Baker Hughes now eligible to develop utility-scale geothermal power plants to supply U.S. military bases</li>
<li>U.S military leveraged Tradewinds procurement process for adoption of resilient energy technologies&nbsp;</li>
</ul>
HOUSTON and LONDON – March 12, 2025 – Baker Hughes, an energy technology company, announced Wednesday that it was selected by the U.S. Air Force and the Department of Defense's Chief Digital and Artificial Intelligence Office (CDAO) to explore opportunities to tap into America's abundant geothermal energy supply to enhance the country's national security.
Having achieved "Awardable" status, Baker Hughes can now explore developing utility-scale geothermal power plants to supply U.S. military bases around the globe with reliable and cost-effective electricity, even during a grid outage. &nbsp;

"U.S. Department Of Defense Grants Baker Hughes 'Awardable' Status For Development Of Geothermal Power Solutions" - Baker Hughes

Telsey Advisory Group analyst Sarang Vora maintains Westrock Coffee (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEST#NASDAQ">WEST</a>) with a Outperform and maintains $9 price target.

WEST

Telsey Advisory Group Maintains Outperform on Westrock Coffee, Maintains $9 Price Target

HC Wainwright &amp; Co. analyst Mitchell Kapoor maintains Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) with a Buy and raises the price target from $73 to $75.

LEGN

HC Wainwright & Co. Maintains Buy on Legend Biotech, Raises Price Target to $75

Telsey Advisory Group analyst Dana Telsey maintains J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) with a Market Perform and maintains $31 price target.

JILL

Telsey Advisory Group Maintains Market Perform on J.Jill, Maintains $31 Price Target

Guidance

Vera Bradley Sees FY26 EPS Of ($0.15) Vs. $0.1 Est.

Stifel analyst Brian Chin maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Hold and lowers the price target from $125 to $110.

Stifel Maintains Hold on Teradyne, Lowers Price Target to $110

Stock Split

NAOV

NanoVibronix Announces 1-for-11 Reverse Stock Split, Effective Mar. 14

Clene, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced new evidence from a cross-regimen, post hoc analysis of long-term survival in HEALEY ALS Platform Trial participants. The analyses further substantiate that treatment with CNM-Au8&#xAE; 30 mg delivers a significant survival benefit for people living with ALS.
New Survival Analyses The analyses compared survival in participants who received CNM-Au8 30 mg (Regimen C) to those of Regimen A in the HEALEY ALS Platform Trial. Regimen A provided a large concurrent control group vs. CNM-Au8 treatment using the same randomization criteria established within the HEALEY master protocol. Long-term survival status, determined through public records and site reporting, was evaluated over a follow-up period of up to 48 months. 78% of participants across both groups received standard ALS background therapy (riluzole, edaravone, or both) at baseline.

Biotech

General

CLNN

Clene Announced New Evidence From A Cross-Regimen, Post Hoc Analysis Of Long-Term Survival In HEALEY ALS Platform Trial Participants

Foremost Clean Energy Ltd. (NASDAQ:<a href="https://www.benzinga.com/stock/FMST#NASDAQ">FMST</a>) (CSE:<a href="https://www.benzinga.com/stock/FAT#CSE">FAT</a>) ("Foremost" or the "Company") is pleased to announce its plans for a $6.5 million exploration program in 2025 (the "Program") across its portfolio of uranium properties in the Athabasca Basin region in northern Saskatchewan. The Program includes the recently announced follow-up drill program on the Hatchet Lake Uranium Property ("Hatchet") as well as planned exploration on the Murphy Lake South, GR, Blackwing, Wolverine, and CLK properties.
&nbsp;
Following an initial evaluation of the exploration potential of the 10 properties under option from Denison Mines Corp. ("Denison")(TSX:<a class="ticker" href="https://www.benzinga.com/stock/DML#TSX">DML</a>, NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DNN#NYSE">DNN</a>), Foremost identified several exploration priorities for 2025. The extensive Program will include drilling, geophysical surveys, and geochemical exploration with a focus on identifying and testing discovery-ready targets across the Athabasca Basin. Utilizing systematic and disciplined testing of discovery-ready drill targets, the program is expected to also generate additional new exploration targets on several under-explored properties.

FMST

TSX:DML

Foremost Clean Energy Announces $6.5M Uranium Exploration Program Across Athabasca Basin As Well As Planned Exploration on The Murphy Lake South, GR, Blackwing, Wolverine, And CLK Properties

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Market Perform and lowers the price target from $6 to $5.

EWCZ

Telsey Advisory Group Maintains Market Perform on European Wax Center, Lowers Price Target to $5

Vera Bradley Sees FY26 Net Revenue Of $280M Vs. $398.545M Est.

NVEE

NV5 Acquires Herman Cx, Terms not Diclosed

Emergent BioSolutions Announces Agreement For Investment Into Swiss Rockets

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4381328-1&amp;h=2654247744&amp;u=http%3A%2F%2Fwww.axcelis.com%2F&amp;a=Axcelis+Technologies">Axcelis Technologies</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today that its Board of Directors has approved an additional $100 million in share repurchase authorization. This approval brings the current outstanding repurchase authorization to $215 million.

Buybacks

ACLS

Axcelis Announces $100M Increase To Share Repurchase Authorization; Approval Brings The Current Outstanding Repurchase Authorization To $215M

Portage Biotech Inc. ("Portage" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>), a clinical-stage immuno-oncology company with a portfolio of innovative therapeutics, today announced the resumption of patient enrollment in the fourth and final cohort of the&nbsp;dose escalation stage&nbsp;for PORT-6, a highly selective A2A antagonist, within its ADPORT-601 Phase 1b clinical trial. Portage had previously paused this trial due to funding concerns; this resumption of the trial underscores the encouraging findings observed in earlier cohorts. After the completion of the PORT-6 arm of the ADPORT-601 study, Portage will evaluate the continuation of the study into its PORT-7 (potent and selective A2B antagonist) and combination arms, on a segment-by-segment basis.
Advancing to this final dose escalation&nbsp;reaffirms Portage's confidence&nbsp;in the safety and therapeutic potential of PORT-6, bringing the Company closer to identifying an optimal dose range for further clinical development.

PRTG

Portage Biotech Resumes Enrollment In Final Cohort Of Dose Escalation For Port-6 In ADPORT-601 Trial

Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $0.07 by 528.57 percent. This is a 372.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $99.96 million which missed the analyst consensus estimate of $107.94 million by 7.39 percent. This is a 24.99 percent decrease over sales of $133.26 million the same period last year.

Earnings

Earnings Misses

Vera Bradley Q4 Adj $(0.30) Misses $0.07 Estimate, Sales $99.96M Miss $107.94M Estimate

Dicker Data chooses CrowdStrike to meet partner demand for the Falcon platform; CrowdStrike most requested cybersecurity solution in ANZ
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fen-us%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=CrowdStrike&amp;index=1&amp;md5=998fe634d7cc0414c8bb1b5476e69264">CrowdStrike</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) today announced a distribution agreement with Dicker Data (ASX: DDR), bringing the industry-leading <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=CrowdStrike+Falcon%26%23174%3B+cybersecurity+platform&amp;index=2&amp;md5=ed0e19c2155a8b1cad7682e56493c548">CrowdStrike Falcon&#xAE; cybersecurity platform</a> to Dicker Data's partners and customers across Australia and New Zealand (ANZ). This partnership expands CrowdStrike's ANZ channel ecosystem, enabling Dicker Data's partner base of leading resellers and managed service providers (MSPs/MSSPs) to drive vendor consolidation and stop breaches with the power of the Falcon platform.
Rising demand in ANZ led to Dicker Data seeking CrowdStrike given the large business opportunity presented by the Falcon platform as well as the mission-critical nature of cybersecurity. Dicker Data is committed to bringing cutting-edge cybersecurity solutions to its partner base serving enterprise, SMB and mid-market organizations across ANZ against advanced threats. With deep expertise in driving AI and cloud transformation services, Dicker Data will leverage the Falcon platform's market-defining AI capabilities, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.crowdstrike.com%2Fplatform%2Fcloud-security%2F&amp;esheet=54222968&amp;newsitemid=20250312968947&amp;lan=en-US&amp;anchor=Falcon%26%23174%3B+Cloud+Security&amp;index=3&amp;md5=d1b4d06b6e21bc41b7fa4e32fe8f3184">Falcon&#xAE; Cloud Security</a> and additional best-in-class modules, empowering partners to modernize security operations while helping customers reduce vendor costs and eliminate coverage gaps caused by fragmented security tools.

CRWD

CrowdStrike Announces New Distribution Agreement With Dicker Data To Meet Rising Cybersecurity Demand Across Australia & New Zealand Enabling Dicker Data's Partner Base Of Leading Resellers And Managed Service Providers To Drive Vendor Consolidation And Stop Breaches With The Power Of The Falcon Platform

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syros Pharmaceuticals, Inc. - SYRS

Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings

Comments

Syros Pharmaceuticals

Syros Pharmaceuticals (SYRS) Opciones

Syros Pharmaceuticals (NASDAQ:SYRS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL